{"entity":{"id":"nct06012435","kind":"trial","name":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial of Docetaxel in non-small-cell lung cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.","summary":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06012435 by Seagen, a wholly owned subsidiary of Pfizer, with 762 participants enrolled, started 2024-02-21 and due to reach its primary completion in 2026-05-18. Interventions recorded: sigvotatug vedotin and docetaxel.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06012435","url":"https://clinicaltrials.gov/study/NCT06012435"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["docetaxel"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06012435","phase":"3","setting":"A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","started":"2024-02-21","startedType":"actual","enrolled":762,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06012435/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}